FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320180332> ?p ?o ?g. }

• W4320180332 abstract "Abstract Background Hepatitis C is associated with metabolic effects and fatty liver disease. The effect of different direct antivirals on the liver steatosis, and the metabolic profile, still needs to be established. The aim of this study is to determine the effect of achieving the sustained virological response after 12 weeks (SVR-12 weeks) with different combinations of direct antiviral drugs, on the hepatic steatosis, and fibrosis presented by laboratory and transient elastography parameters. Our study population is nondiabetic, chronically infected HCV Egyptian patients and naïve to any form of HCV treatment. Methods This cohort study was carried on 100 nondiabetic HCV treatment-naïve patients attending the Hepatology Clinic, in the Gastroenterology and Hepatology Department, Ain Shams University, and Kobry El Koba Military Hospital. The patients were divided into four groups according to their treatment regimens as follows: group A: 25 patients who received sofosbuvir (400 mg) and daclatasvir (60 mg) daily for 12 weeks; group B: 25 patients who received sofosbuvir (400 mg) and ledipasvir (90 mg) daily for 12 weeks; group C: 25 patients who received ombitasvir (12.5 mg), paritaprevir (75 mg), and ritonavir (50 mg) daily for 12 weeks; and group D: 25 patients who received sofosbuvir (400 mg) and simeprevir (150 mg) daily for 12 weeks. All patients were subjected to the following investigations: HCV quantitative PCR before and after 12 weeks of treatment, clinical and laboratory metabolic evaluation including alfa-fetoprotein level, thyroid profile assessment, ferritin level, pelvi-abdominal ultrasound, and FibroScan examination. Results All patients achieved SVR after 12 weeks. FibroScan median decreased ( P < 0.001) from 19.29 ± 6.97 kPa at baseline to 14.15 ± 6.48 kPa at SVR12. NAFLD score median increased from 1.88 (1.49–2.22) at baseline to 2.01 (1.61–2.33) after 12 weeks of treatment. The highest level of NAFLD score was in group C, and the lowest was in group B. The BMI mean decreased from 28.31 ± 1.53 at baseline to 28.07 ± 1.52 at SVR12. HbA1C level mean decreased from 5.73 ± 0.23 at baseline to 5.40 ± 0.24 at SVR12. In addition, liver enzymes, cholesterol, triglycerides, APRI score (AST-platelet ratio index), and HBA1C decreased after 12-week treatment with a statistically significant difference, while the mean LDL increased after 12 weeks of treatment. Conclusions DAAs affect the metabolic profile of the treated patients. There is a noticed improvement in the FibroScan, NAFLD score, and lipid profile after achieving the SVR-12 weeks. However, LDL is increased after viral cure, mostly due to viral-host molecular interaction." @default.
• W4320180332 created "2023-02-13" @default.
• W4320180332 creator A5029593382 @default.
• W4320180332 creator A5032967352 @default.
• W4320180332 creator A5036277067 @default.
• W4320180332 creator A5041616852 @default.
• W4320180332 creator A5053957158 @default.
• W4320180332 creator A5062685473 @default.
• W4320180332 creator A5081033206 @default.
• W4320180332 date "2023-02-13" @default.
• W4320180332 modified "2023-10-16" @default.
• W4320180332 title "The effect of different direct antivirals on hepatic steatosis in nondiabetic and naïve hepatitis C-infected Egyptian patients" @default.
• W4320180332 cites W1965208459 @default.
• W4320180332 cites W1981501164 @default.
• W4320180332 cites W1997865776 @default.
• W4320180332 cites W2001022777 @default.
• W4320180332 cites W2047919099 @default.
• W4320180332 cites W2051984446 @default.
• W4320180332 cites W2072060351 @default.
• W4320180332 cites W2111335059 @default.
• W4320180332 cites W2112496618 @default.
• W4320180332 cites W2158383761 @default.
• W4320180332 cites W2524545167 @default.
• W4320180332 cites W2578013986 @default.
• W4320180332 cites W2615797938 @default.
• W4320180332 cites W2779425746 @default.
• W4320180332 cites W2790029625 @default.
• W4320180332 cites W2790339633 @default.
• W4320180332 cites W2883643888 @default.
• W4320180332 cites W2937021044 @default.
• W4320180332 cites W2963085893 @default.
• W4320180332 cites W2966195650 @default.
• W4320180332 cites W2992772421 @default.
• W4320180332 cites W3088020815 @default.
• W4320180332 cites W3129065841 @default.
• W4320180332 cites W4229366608 @default.
• W4320180332 doi "https://doi.org/10.1186/s43162-023-00197-1" @default.
• W4320180332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36816629" @default.
• W4320180332 hasPublicationYear "2023" @default.
• W4320180332 type Work @default.
• W4320180332 citedByCount "0" @default.
• W4320180332 crossrefType "journal-article" @default.
• W4320180332 hasAuthorship W4320180332A5029593382 @default.
• W4320180332 hasAuthorship W4320180332A5032967352 @default.
• W4320180332 hasAuthorship W4320180332A5036277067 @default.
• W4320180332 hasAuthorship W4320180332A5041616852 @default.
• W4320180332 hasAuthorship W4320180332A5053957158 @default.
• W4320180332 hasAuthorship W4320180332A5062685473 @default.
• W4320180332 hasAuthorship W4320180332A5081033206 @default.
• W4320180332 hasBestOaLocation W43201803321 @default.
• W4320180332 hasConcept C126322002 @default.
• W4320180332 hasConcept C203014093 @default.
• W4320180332 hasConcept C2522874641 @default.
• W4320180332 hasConcept C2775934546 @default.
• W4320180332 hasConcept C2775999097 @default.
• W4320180332 hasConcept C2776175330 @default.
• W4320180332 hasConcept C2776408679 @default.
• W4320180332 hasConcept C2776455275 @default.
• W4320180332 hasConcept C2776979040 @default.
• W4320180332 hasConcept C2777100407 @default.
• W4320180332 hasConcept C2777766500 @default.
• W4320180332 hasConcept C2778390639 @default.
• W4320180332 hasConcept C2778772119 @default.
• W4320180332 hasConcept C2778785139 @default.
• W4320180332 hasConcept C2778867932 @default.
• W4320180332 hasConcept C2778986448 @default.
• W4320180332 hasConcept C2779134260 @default.
• W4320180332 hasConcept C2780040827 @default.
• W4320180332 hasConcept C2780826214 @default.
• W4320180332 hasConcept C2908647359 @default.
• W4320180332 hasConcept C41260117 @default.
• W4320180332 hasConcept C71924100 @default.
• W4320180332 hasConcept C90924648 @default.
• W4320180332 hasConcept C99454951 @default.
• W4320180332 hasConceptScore W4320180332C126322002 @default.
• W4320180332 hasConceptScore W4320180332C203014093 @default.
• W4320180332 hasConceptScore W4320180332C2522874641 @default.
• W4320180332 hasConceptScore W4320180332C2775934546 @default.
• W4320180332 hasConceptScore W4320180332C2775999097 @default.
• W4320180332 hasConceptScore W4320180332C2776175330 @default.
• W4320180332 hasConceptScore W4320180332C2776408679 @default.
• W4320180332 hasConceptScore W4320180332C2776455275 @default.
• W4320180332 hasConceptScore W4320180332C2776979040 @default.
• W4320180332 hasConceptScore W4320180332C2777100407 @default.
• W4320180332 hasConceptScore W4320180332C2777766500 @default.
• W4320180332 hasConceptScore W4320180332C2778390639 @default.
• W4320180332 hasConceptScore W4320180332C2778772119 @default.
• W4320180332 hasConceptScore W4320180332C2778785139 @default.
• W4320180332 hasConceptScore W4320180332C2778867932 @default.
• W4320180332 hasConceptScore W4320180332C2778986448 @default.
• W4320180332 hasConceptScore W4320180332C2779134260 @default.
• W4320180332 hasConceptScore W4320180332C2780040827 @default.
• W4320180332 hasConceptScore W4320180332C2780826214 @default.
• W4320180332 hasConceptScore W4320180332C2908647359 @default.
• W4320180332 hasConceptScore W4320180332C41260117 @default.
• W4320180332 hasConceptScore W4320180332C71924100 @default.
• W4320180332 hasConceptScore W4320180332C90924648 @default.
• W4320180332 hasConceptScore W4320180332C99454951 @default.
• W4320180332 hasIssue "1" @default.
• W4320180332 hasLocation W43201803321 @default.

• next